Redwood Pharma signs agreement regarding GMP production

Redwood Pharma has signed an agreement with CARBOGEN AMCIS, which is one of the leading supplier of services within pharmaceutical development.  CARBOGEN AMCIS will avail Redwood Pharma production of new drug candidate RP101 for the subsequent clinical trial.

As an integral step in Redwood Pharma’s activities in preparation for the clinical trial of RP101 in patients with dry eye disease, CARBOGEN AMCIS has been awarded the contract for production of RP101, the company’s new drug candidate according to Good Manufacturing Practice (GMP). CARBOGEN AMCIS has capabilities within development and production of pharmaceuticals, as well as global manufacturing facilities. The firm is based in Switzerland. CARBOGEN AMCIS’ integrated services offer its customers access to innovative, up-to-date and safe pharmaceutical development solutions that allow customers to optimize their available resources. For more information regarding CARBOGEN AMCIS, visit

Martin Vidaeus, CEO of Redwood Pharma, comments, ” CARBOGEN AMCIS is a contract manufacturing organization with many years’ experience and with a broad range of technical capabilities for our class of product. The firm will now assist Redwood Pharma with manufacturing of RP101, and with this agreement, we strengthen our development expertise and ensure a stable path towards the clinical trial.” 

For more information:
Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29


Hans Ageland – Chief Operation Officer (COO) Redwood Pharma AB (publ.)
Tel: 073-334 66 01

This information is information that Redwood Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at June 29, 2017.

About Redwood Pharma
Redwood Pharma develops ophthalmic products for unmet medical needs. The Company’s first project is the development of drug candidate RP101 with a known active substance against chronic dry eye in postmenopausal women who have moderate to severe symptoms. With the drug delivery platform IntelliGel® the release of active substances is controlled. Through the use of IntelliGel, Redwood Pharma can also improve dosing of other established drugs. Redwood Pharma’s strength lies in formulation and early clinical development. Revenues will be generated through licensing agreements with pharmaceutical companies that have capabilities to manufacture and sell commercial products worldwide.

Redwood Pharma AB (publ.) is listed on AktieTorget, a Swedish Multilateral Trading Facility (Ticker: REDW.ST, ISIN: SE008294789).
For more information visit:


CARBOGEN AMCIS AG ( is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development allowing customers to make the best use of available resources. Company’s facilities operate in a fully cGMP compliant infrastructure, including dedicated Highly Potent facilities and Clean Room suites for Bioconjugation. CARBOGEN AMCIS AG is owned by Dishman Pharmaceuticals and Chemicals Ltd, Ahmedabad, India. 

About Us

The firm is a pharmaceutical company focused on development of new ophthalmic therapies where there are clear and unmet clinical needs. Redwood Pharma’s lead product in development is a new eye drop designed to treat an underlying cause of chronic Dry Eye Disease in post-menopausal women. Through the IntelliGel® drug delivery platform, a technology developed for controlled release, the company creates exciting opportunities to improve existing therapies and also to develop new ones.


Documents & Links